Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Revenue (Tables)

v3.22.2.2
Note 3 - Revenue (Tables)
9 Months Ended
Sep. 30, 2022
Notes Tables  
Disaggregation of Revenue [Table Text Block]
   

Three Months Ended September 30,

   

Nine Months Ended September 30,

 
   

2022

   

2021

   

2022

   

2021

 

Seagen

  $ 155     $ (280 )   $ 3,074     $ 424  

AstraZeneca

    4,404       1,607       9,026       18,309  

Servier

    258       1,867       5,223       3,379  

Genentech

    553       863       2,733       863  

Total Revenue

  $ 5,370     $ 4,057     $ 20,056     $ 22,975  
Revenue From Contract With Customer, Milestone Payments [Table Text Block]
   

Research, Development, Regulatory & Commercial Milestones

   

Sales Milestones

 

AstraZeneca

  $ 702     $ 3,925  

Servier

    118       88  

Seagen

    754       450  

Boston Pharmaceuticals

    88       265  

Genentech

    834       600  

Total potential milestone payments

  $ 2,496     $ 5,328